Study to Evaluate Patients With Cerebrotendinous Xanthomatosis

  • STATUS
    Recruiting
  • participants needed
    12
  • sponsor
    Retrophin, Inc.
Updated on 19 February 2024

Summary

The study is made up of two cohorts: a randomized double-blind crossover (placebo withdrawal with rescue) study among patients 16 years of age (adult cohort) and an open-label dose titration study among pediatric patients 1 month and <16 years of age (pediatric cohort)

Details
Condition Cyclophosphamide, CEREBROTENDINOUS XANTHOMATOSIS
Age 1-100 years
Treatment Placebo, Blinded CDCA 250 mg TID, Open-Label CDCA 250 mg TID, Rescue Medication CDCA 250 mg TID, CDCA Weight-Based Dose TID
Clinical Study IdentifierNCT04270682
SponsorRetrophin, Inc.
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

Male or female at least 1 month or older at screening
Clinical diagnosis of CTX with biochemical confirmation
Women of childbearing potential must agree to the use of one highly reliable method of contraception during the study, plus one additional barrier method during sexual activity
Males must be surgically sterile, or males and their sexual partners must together agree to use medically accepted methods of contraception that are considered highly reliable during the course of the study

Exclusion Criteria

Genetic testing does not confirm CTX
Malabsorption disorder or confounding inflammatory gastrointestinal condition (for example, irritable bowel syndrome)
Documented history of heart failure
Treated with medications which impact bile acid absorption such as bile acid sequestering agents (eg, cholestyramine, colestipol, aluminum-based antacids
Treated with cholic acid medication
Female patient who is pregnant, plans to become pregnant during the course of the study, or is breastfeeding
Positive at screening for the human immunodeficiency virus (HIV) or markers indicating acute or chronic hepatitis B infection or hepatitis C infection
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.